Galecto (GLTO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
31 Dec, 2025Voting matters and shareholder proposals
Approval sought for conversion of Series B and Series C Non-Voting Convertible Preferred Stock into common stock, subject to Nasdaq Listing Rule 5635(a).
Proposal to amend the Certificate of Incorporation to increase authorized common stock from 300,000,000 to 500,000,000.
Proposal to redomesticate from Delaware to the Cayman Islands, including adoption of new memorandum and articles of association.
Approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan.
Proposal to adjourn or postpone the meeting if necessary to solicit additional votes.
Executive summary
Special meeting called to approve key corporate actions including stock conversions, capital increase, redomestication, and new equity plans.
Board recommends voting in favor of all proposals, citing benefits such as increased flexibility, cost savings, and alignment with shareholder interests.
Board of directors and corporate governance
Board remains unchanged through redomestication; directors' terms and classes preserved.
Board retains authority to issue additional shares and fill vacancies; classified board structure maintained.
New directors affiliated with major investors appointed following recent transactions.
Latest events from Galecto
- Cash position of $535M supports pipeline progress; net loss driven by R&D acquisition costs.GLTO
Q4 202520 Mar 2026 - Damora advances potent CALR-targeted therapies for ET and MF, aiming for broad clinical impact.GLTO
Leerink Global Healthcare Conference 20269 Mar 2026 - BRM-1420, a dual ENL-YEATS/FLT3 inhibitor, advances toward clinical trials for high-risk AML.GLTO
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202524 Dec 2025 - Shareholders will vote on key proposals to support growth, redomestication, and new equity plans.GLTO
Proxy Filing16 Dec 2025 - Advancing preclinical antibody and small molecule therapies for blood cancers after major PIPE raise.GLTO
Registration Filing16 Dec 2025 - Annual meeting to vote on director elections, stock issuance, and auditor ratification.GLTO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, stock conversion, auditor, and review governance and compensation.GLTO
Proxy Filing2 Dec 2025 - Key votes include director elections, stock issuance approval, and auditor ratification.GLTO
Proxy Filing2 Dec 2025 - Acquisition expands blood cancer pipeline and secures $285M funding for clinical milestones through 2029.GLTO
M&A Announcement17 Nov 2025